High Growth Forecasted for The Global Pain Therapeutics Market, 3rd Edition

Business Wire, Nov 4, 2008

Table 13.6 Global Sales of Duragesic 2001-2008 ($ mn)

Graph 13.4 Global Sales of Duragesic 2001-2007

Table 13.7 Financial Forecast of Duragesic Sales 2007-2013 ($ mn)

Table 13.8 Global Sales of Kadian 2002-2008 ($ mn)

Graph 13.5 Global Sales of Kadian 2002-2007

Table 13.9 Global Sales of Ultracet/Ultram 2001-2008 ($ mn)

Graph 13.6 Global Sales of Ultracet/Ultram 2001-2007

Table 13.10 Global Sales of Avinza 2003-2008 ($ mn)

Graph 13.7 Global Sales of Avinza 2003-2007

Table 13.11 Global Sales of Actiq 2002-2008 ($ mn)

Graph 13.8 Global Sales of Actiq 2002-2007

Table 13.12 Financial Forecast of Cephalon's Pain Franchise 2007-2013 ($ mn)

Table 13.13 Financial Forecast of the Global Opioid Market 2007-2013 ($ mn)

Graph 13.9 Financial Forecast of the Global Opioid Market 2007-2013

Table 14.1Sales of Triptan Drugs 2001-2008

Graph 14.1 Sales of Triptan Drugs 2001-2007

Table 14.2 Sales of Leading Migraine Therapies 2007

Graph 14.2 Leading Migraine Therapies, Market Share 2007

Graph 14.3 Geographic Market Share of Leading Triptan-Based Migraine Therapies 2007

Table 14.3 Sales of Imitrex/Imigran 2001-2008 ($ mn)

Graph 14.4 Sales of Imitrex/Imigran 2001-2007

Table 14.4 Financial Forecast of Imitrex/Imigran Sales 2007-2013 ($ mn)

Table 14.5 Sales of Zomig 2001-2008 ($ mn)

Graph 14.5 Sales of Zomig 2001-2007

Table 14.6 Financial Forecast of Zomig Sales 2007-2013 ($ mn)

Table 14.7 Sales of Relpax 2001-2008 ($ mn)

Graph 14.6 Sales of Relpax 2001-2007

Table 14.8 Sales of Maxalt 2001-2008 ($ mn)

Graph 14.7 Sales of Maxalt 2001-2007

Table 14.9 Sales of Frova 2005-2008 ($ mn)

Graph 14.8 Sales of Frova 2005-2007

Table 14.10 Financial Forecast of Triptans 2007-2013 ($ mn)

Table 15.1 Leading Anticonvulsants, Global Sales 2007

Graph 15.1 Leading Anticonvulsants, Market Share 2007

Table 15.2 Sales Growth in the Anticonvulsants Market 2001-2008 ($ mn)

Graph 15.2 Sales Growth in the Anticonvulsants Market 2001-2007 ($ mn)

Table 15.3 Leading Anticonvulsant Indications

Table 15.4 Sales of Lyrica 2004-2008 ($ mn)

Graph 15.3 Sales of Lyrica 2004-2007

Table 15.5 Financial Forecast of Lyrica Sales 2007-2013 ($ mn)

Table 15.6 Sales of Neurontin 2001-2008 ($ mn)

Graph 15.4 Sales of Neurontin 2001-2007

Table 15.7 Sales of Topamax 2001-2008 ($ mn)

Graph 15.5 Sales of Topamax 2001-2007

Table 15.8 Financial Forecast of Topamax Sales 2007-2013 ($ mn)

Table 15.9 Sales of Depakote 2001-2008 ($ mn)

Graph 15.6 Sales of Depakote 2001-2007

Table 15.10 Financial Forecast of Depakote Sales 2007-2013 ($ mn)

Table 15.11 Sales of Lamictal 2001-2008 ($ mn)

Graph 15.7 Sales of Lamictal 2001-2007

Table 15.12 Financial Forecast of Lamictal Sales 2007-2013 ($ mn)

Table 15.13 Sales of Trileptal 2001-2008 ($ mn)

Graph 15.8 Sales of Trileptal 2001-2007

Table 15.14 Sales of Tegretol 2001-2008 ($ mn)

Graph 15.9 Sales of Tegretol 2001-2007

Table 15.15 Financial Forecast of the Anticonvulsant Market 2007-2013 ($ mn)

Table 16.2 Sales of Celebrex 2003-2008 ($ mn)

Graph 16.1 Sales of Celebrex 2003-2007

Table 16.3 Sales of Arcoxia 2003-2008 ($ mn)

Graph 16.2 Sales of Arcoxia 2003-2007